Michael Humphries

1.2k total citations
33 papers, 871 citations indexed

About

Michael Humphries is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Molecular Biology. According to data from OpenAlex, Michael Humphries has authored 33 papers receiving a total of 871 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 10 papers in Physiology and 7 papers in Molecular Biology. Recurrent topics in Michael Humphries's work include Asthma and respiratory diseases (9 papers), Respiratory and Cough-Related Research (7 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (7 papers). Michael Humphries is often cited by papers focused on Asthma and respiratory diseases (9 papers), Respiratory and Cough-Related Research (7 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (7 papers). Michael Humphries collaborates with scholars based in United States, China and Switzerland. Michael Humphries's co-authors include Mary E. Reyland, G.A. Ellard, Angela M. Ohm, Lee Carpenter, Trevor J. Biden, Keiichi I. Nakayama, Francesco Patalano, Changzheng Wang, Donald Banerji and Steven M. Anderson and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Michael Humphries

31 papers receiving 848 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Humphries United States 13 354 287 267 118 97 33 871
Shizuo Hasegawa Japan 17 224 0.6× 345 1.2× 291 1.1× 70 0.6× 85 0.9× 41 790
María Isidoro‐García Spain 18 310 0.9× 178 0.6× 345 1.3× 69 0.6× 77 0.8× 90 1.1k
Thomas Trian France 19 384 1.1× 471 1.6× 550 2.1× 76 0.6× 80 0.8× 40 1.1k
Annalisa Schirinzi Italy 11 257 0.7× 126 0.4× 59 0.2× 59 0.5× 44 0.5× 24 699
Ronald G. Crystal United States 7 259 0.7× 451 1.6× 53 0.2× 50 0.4× 78 0.8× 7 777
Ulla Westin Sweden 18 206 0.6× 154 0.5× 197 0.7× 115 1.0× 59 0.6× 30 782
P. Vic France 14 189 0.5× 592 2.1× 725 2.7× 69 0.6× 103 1.1× 21 1.1k
Shiro Seto Japan 13 215 0.6× 76 0.3× 60 0.2× 130 1.1× 184 1.9× 24 586
Komgrid Charngkaew Thailand 12 263 0.7× 91 0.3× 46 0.2× 114 1.0× 98 1.0× 23 642
Alejandro Rojas‐Fernández Chile 15 309 0.9× 61 0.2× 78 0.3× 98 0.8× 168 1.7× 36 669

Countries citing papers authored by Michael Humphries

Since Specialization
Citations

This map shows the geographic impact of Michael Humphries's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Humphries with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Humphries more than expected).

Fields of papers citing papers by Michael Humphries

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Humphries. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Humphries. The network helps show where Michael Humphries may publish in the future.

Co-authorship network of co-authors of Michael Humphries

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Humphries. A scholar is included among the top collaborators of Michael Humphries based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Humphries. Michael Humphries is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bazhenova, Lyudmila, John Hodgson, D. Ross Camidge, et al.. (2025). Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non–Small-Cell Lung Cancer According to ALK Fusion and Mutation Status. Clinical Lung Cancer. 26(7). e503–e513.e11. 1 indexed citations
2.
Lin, Huamao Mark, Yu Yin, Huifeng Niu, et al.. (2022). Real-world ALK Testing Trends in Patients With Advanced Non–Small-Cell Lung Cancer in the United States. Clinical Lung Cancer. 24(1). e39–e49. 8 indexed citations
3.
Humphries, Michael, et al.. (2022). The cost-effectiveness of brigatinib in adult patients with ALK inhibitor–naive ALK-positive non–small cell lung cancer from a US perspective. Journal of Managed Care & Specialty Pharmacy. 28(9). 970–979. 4 indexed citations
4.
Li, Jing, Jing Yang, Lingfei Kong, et al.. (2020). Efficacy and safety of omalizumab in patients with moderate-to-severe asthma: An analytic comparison of data from randomized controlled trials between Chinese and Caucasians. Asian Pacific Journal of Allergy and Immunology. 40(3). 223–231. 8 indexed citations
5.
Wedzicha, Jadwiga A., Nanshan Zhong, Masakazu Ichinose, et al.. (2017). Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study. International Journal of COPD. Volume 12. 339–349. 30 indexed citations
6.
Vogelmeier, Claus, Nanshan Zhong, Michael Humphries, et al.. (2016). Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis. International Journal of COPD. Volume 11. 3189–3197. 12 indexed citations
7.
Sannigrahi, Santanu, Tieying Sun, Yijiang Huang, et al.. (2015). Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study. International Journal of COPD. 10. 57–57. 18 indexed citations
8.
Sannigrahi, Santanu, Changzheng Wang, Xiangdong Zhou, et al.. (2015). LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. International Journal of COPD. 10. 1015–1015. 132 indexed citations
9.
Zhong, Nanshan, Changzheng Wang, Xiangdong Zhou, et al.. (2014). Late-breaking abstract: Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol/fluticasone combination (SFC) in patients with COPD: The LANTERN study. European Respiratory Journal. 44(Suppl 58). P2815–P2815. 8 indexed citations
10.
Davies, Kurtis D., Michael Humphries, Francis X. Sullivan, et al.. (2011). Single-Agent Inhibition of Chk1 Is Antiproliferative in Human Cancer Cell Lines In Vitro and Inhibits Tumor Xenograft Growth In Vivo. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. 19(7). 349–363. 22 indexed citations
11.
Ohm, Angela M., et al.. (2011). Regulated Binding of Importin-α to Protein Kinase Cδ in Response to Apoptotic Signals Facilitates Nuclear Import. Journal of Biological Chemistry. 286(41). 35716–35724. 38 indexed citations
12.
Seimon, Tracie A., Angela M. Ohm, Michael Humphries, & Mary E. Reyland. (2007). Induction of Apoptosis Is Driven by Nuclear Retention of Protein Kinase Cδ. Journal of Biological Chemistry. 282(31). 22307–22314. 75 indexed citations
13.
Humphries, Michael, et al.. (2006). Suppression of Apoptosis in the Protein Kinase Cδ Null Mouse in Vivo. Journal of Biological Chemistry. 281(14). 9728–9737. 117 indexed citations
14.
Jackson, Desmond N., Zheng Yang, Keiko Nakayama, et al.. (2005). Suppression of cell migration by protein kinase Cδ. Oncogene. 24(18). 3067–3072. 44 indexed citations
15.
Zhong, Nan, et al.. (2004). Salmeterol/Fluticasone Propionate in???a???Single Inhaler is Superior to Budesonide Alone in Control of Chinese Asthmatic Adults. Clinical Drug Investigation. 24(10). 583–592. 4 indexed citations
16.
Carpenter, Lee, et al.. (2001). PKCδ Is Required for Mitochondrial-dependent Apoptosis in Salivary Epithelial Cells. Journal of Biological Chemistry. 276(32). 29719–29728. 118 indexed citations
17.
He, Qing‐Yu, et al.. (1995). The perioperative use of ceftriaxone as infection prophylaxis in neurosurgery. Clinical Neurology and Neurosurgery. 97(4). 285–289. 11 indexed citations
18.
Ellard, G.A., et al.. (1993). Cerebrospinal Fluid Drug Concentrations and the Treatment of Tuberculous Meningitis. American Review of Respiratory Disease. 148(3). 650–655. 100 indexed citations
19.
Humphries, Michael. (1980). Loud and Clear? Summary of a Study of Curriculum Dissemination in Further and Higher Education. Project Report 3: Summary..
20.
Humphries, Michael. (1958). Performance as a function of control-display relations, positions of the operator, and locations of the control.. Journal of Applied Psychology. 42(5). 311–316. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shizuo Hasegawa Breakdown of academic impact, for papers by María Isidoro‐García Breakdown of academic impact, for papers by Thomas Trian Breakdown of academic impact, for papers by Annalisa Schirinzi Breakdown of academic impact, for papers by Ronald G. Crystal Breakdown of academic impact, for papers by Ulla Westin Breakdown of academic impact, for papers by P. Vic Breakdown of academic impact, for papers by Shiro Seto Breakdown of academic impact, for papers by Komgrid Charngkaew Breakdown of academic impact, for papers by Alejandro Rojas‐Fernández
Rankless by CCL
2026